EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data

Petra Belohlavkova iD, Daniela Zackova iD, Hana Klamova, Edgar Faber, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Ivana Jeziskova, Katerina Machova Polakova, Pavel Zak, Tereza Jurkova und 2 weitere

Cancer Medicine · 2024

DOI: 10.1002/cam4.70158 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Petra Belohlavkova und 13 weiteren Autor:innen. Beteiligte Einrichtung: 4th Department of Internal Medicine and Haematology, University Hospital Hradec Kralove and Charles University, Prague, Czech Republic. Hauptthemen laut MEDLINE: Imatinib Mesylate, Pyrimidines, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The project National Institute for Cancer Research The project National Institute for Cancer Research, DRO and the Cooperatio Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world clinical practice.

Methods

A propensity score analysis was performed to eliminate imbalances between the treatment groups. In the analysis, 163 patients in the nilotinib group and 163 patients in the matched imatinib group were retrospectively evaluated.

Results

Nilotinib‐treated patients achieved complete cytogenetic response (CCyR) and major molecular response more rapidly than imatinib‐treated patients. However, there was no significant difference in 5‐year overall survival (OS) or progression‐free survival (PFS) between the two groups (OS: 94.3% vs. 90.5%, p = 0.602; PFS: 92.9% vs. 88.0%, p = 0.614). Nilotinib‐treated patients had a higher failure‐free survival (FFS) and event‐free survival (EFS) than imatinib‐treated patients (FFS: 71.7% vs. 54.3%, p = 0.040; EFS: 71.7% vs. 53.5%, p = 0.025).

Conclusions

This retrospective analysis from clinical practice did not confirm any benefit of frontline nilotinib treatment for OS and PFS; however, it did demonstrate higher FFS and EFS in the nilotinib cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Imatinib MesylatePyrimidinesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHumansFemaleMaleMiddle AgedRetrospective StudiesAdultAgedTreatment OutcomeAntineoplastic AgentsProtein Kinase InhibitorsPropensity ScoreProgression-Free SurvivalYoung Adult

Stichwörter der Autor:innen

chronic myeloid leukemiafirst‐line treatmentimatinibnilotinib

Substanzen

nilotinibImatinib MesylatePyrimidinesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • 4th Department of Internal Medicine and Haematology, University Hospital Hradec Kralove and Charles University, Prague, Czech Republic.
  • Department of Internal Medicine-Haematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic.
  • Institute of Haematology and Blood Transfusion, Prague, Czech Republic.
  • Department of Haemato-oncology, University Hospital Olomouc and Palacky University, Olomouc, Czech Republic.
  • Department of Haemato-oncology, University Hospital Plzen and Charles University, Plzen, Czech Republic.
  • Department of Haemato-oncology, University Hospital Ostrava and Ostrava University, Ostrava, Czech Republic.

ORCID-Profile: Petra Belohlavkova, Daniela Zackova

Förderung

  • The project National Institute for Cancer Research The project National Institute for Cancer Research
  • DRO and the Cooperatio Program

Zitieren

APA

Belohlavkova, P., Zackova, D., Klamova, H., Faber, E., Karas, M., Stejskal, L., Cmunt, E., Cerna, O., Jeziskova, I., Machova Polakova, K., Zak, P., Jurkova, T., Chrapava, M., & Mayer, J. (2024). Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data. Cancer Medicine. https://doi.org/10.1002/cam4.70158

Vancouver

Belohlavkova P, Zackova D, Klamova H, Faber E, Karas M, Stejskal L, et al. Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data. Cancer Medicine. 2024. doi:10.1002/cam4.70158

BibTeX
@article{Belohlavkova2024,
  author = {Belohlavkova, Petra and Zackova, Daniela and Klamova, Hana and Faber, Edgar and Karas, Michal and Stejskal, Lukas and Cmunt, Eduard and Cerna, Olga and Jeziskova, Ivana and Machova Polakova, Katerina and Zak, Pavel and Jurkova, Tereza and Chrapava, Marika and Mayer, Jiri},
  title = {Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70158}
}
Kostenlos starten →